TW200732308A - Substituted 4-aminoquinazoline derivatives, preparation thereof and therapeutic application thereof - Google Patents

Substituted 4-aminoquinazoline derivatives, preparation thereof and therapeutic application thereof

Info

Publication number
TW200732308A
TW200732308A TW095137552A TW95137552A TW200732308A TW 200732308 A TW200732308 A TW 200732308A TW 095137552 A TW095137552 A TW 095137552A TW 95137552 A TW95137552 A TW 95137552A TW 200732308 A TW200732308 A TW 200732308A
Authority
TW
Taiwan
Prior art keywords
alkylene
alkyl
aryl
optionally substituted
nrarb
Prior art date
Application number
TW095137552A
Other languages
Chinese (zh)
Inventor
Jean Michel Augereau
Gilles Courtemanche
Pierre Despeyroux
Michel Geslin
Anne Thomas
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36645639&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200732308(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of TW200732308A publication Critical patent/TW200732308A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The invention relates to 4-aminoquinazoline derivatives of general formula (I), in which: A, B = optionally substituted C1-4-alkylene; L = single bond, C1-2-alkylene, -CH=CH- or -C≡C-; the groups C1-2-alkylene and -CH=CH- being optionally substituted, or L = cyctoprop-1,2-diyl;R = H, C1-5-alkyl, C1-3-fluoroalkyl, C3-6-cydoalkyl, - C(O)C1-3-alkyl, C1-3-alkylene-C3-6-cycloalkyl, -CH2-C≡CH, C2-4-alkylene-NRaRb or C1-3-alkylene-X-C1-3-alkyl in which X = O, SO2; R1 = aryl or heteroaryl; optionally substituted; R2 and R3 = H, C1-3-alkyl or C1-3-fluoroalkyl, or alternatively R2 and R3 together form a cycloprop-1,1-diyl; R4 = H, C1-5-alkyl, C1-3-fluoroalkyl, C1-5-alkoxy, -SF5, C1-3-alkylene-X-C1-3-alkyl in which X = O or SO2, C1-5-alkylene-NRaRb, an aryl or a heteroaryl, which are optionally substituted; R5 = H, halogen, C1-5-alkyl, C1-3-fluoroalkyl, C1-5-alkoxy, C3-6-cycloalkyl, C1-3-alkylene-C3-6-cycloalkyl, C1-3-alkylene-O-C1-3-alkyl, C1-3-alkylene-(OH) or C1-3-alkylene-X-C1-3-alkyl in which X = S, SO or SO2, or alternatively R5 = -NRaRb, C1-3-alkylene-NRaRb, aryl, C1-3-alkylene-aryl, -O-aryl, C1-3-alkylene-O-aryl, C1-3-alkylene-O-C1-3-alkylene-aryl, heteroaryl or C1-3-alkylene-heteroaryl, which are optionally substituted, or R5 = heterocycle optionally substituted with C1-3-alkyl, -C(O)C1-3-alkyl, -C(O)C1-3-fluoroalkyl, C1-3-alkylene-C3-6-cycloalkyl, C1-3-alkylene-aryl, C1-3-alkylene-heteroaryl, which are optionally substituted; R7 = H, halogen, C1-5-alkyl, C1-3-fluoroalkyl, C1-5-alkoxy, -COOH, -C(O)O-C1-3-alkyl, C1-3-fluoroalkoxy, C1-3-alkylene-(OH), -NO2, -CN or -X-C1-3-alkyl in which X represents S, SO or SO2, or alternatively R7 = -NRaRb, C1-3-alkylene-NRaRb, -C(O)-NRaRb, -C(o)-C1-3-alkyl, aryl, -O-aryl or heteroaryl, which are optionally substituted; in the form of base or of acid-addition salt, and also in the form of hydrate or solvate.
TW095137552A 2005-10-12 2006-10-12 Substituted 4-aminoquinazoline derivatives, preparation thereof and therapeutic application thereof TW200732308A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0510409A FR2891829A1 (en) 2005-10-12 2005-10-12 4-AMINO-QUINAZOLINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF

Publications (1)

Publication Number Publication Date
TW200732308A true TW200732308A (en) 2007-09-01

Family

ID=36645639

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095137552A TW200732308A (en) 2005-10-12 2006-10-12 Substituted 4-aminoquinazoline derivatives, preparation thereof and therapeutic application thereof

Country Status (5)

Country Link
AR (1) AR056688A1 (en)
FR (1) FR2891829A1 (en)
TW (1) TW200732308A (en)
UY (1) UY29857A1 (en)
WO (1) WO2007042669A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2009108280A (en) 2006-08-08 2010-09-20 Санофи-Авентис (Fr) Arylamino-arylalkyl-substituted imidazolidine-2,4-dione, methods for their preparation containing these compounds and their use
RU2010152290A (en) * 2008-05-22 2012-06-27 Аллерган, Инк. (Us) BICYCLIC COMPOUNDS POSSESSING ACTIVITY AT A CRCR4 RECEPTOR
UY31968A (en) 2008-07-09 2010-01-29 Sanofi Aventis NEW HETEROCYCLIC DERIVATIVES, THEIR PROCESSES FOR THEIR PREPARATION, AND THEIR THERAPEUTIC USES
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
SG178880A1 (en) 2009-08-26 2012-04-27 Sanofi Sa Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2012120052A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
EP2683699B1 (en) 2011-03-08 2015-06-24 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120054A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US10588907B2 (en) 2015-06-04 2020-03-17 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
CN109640987B (en) 2016-03-16 2022-12-02 库拉肿瘤学公司 Bridged bicyclic inhibitors of MENIN-MLL and methods of use
CN114539284A (en) 2016-03-16 2022-05-27 库拉肿瘤学公司 Substituted MENIN-MLL inhibitors and methods of use
EP3601249A4 (en) 2017-03-24 2020-12-16 Kura Oncology, Inc. Methods for treating hematological malignancies and ewing's sarcoma
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
EP3684361A4 (en) 2017-09-20 2021-09-08 Kura Oncology, Inc. Substituted inhibitors of menin-mll and methods of use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0126087A1 (en) * 1982-09-24 1984-11-28 Beecham Group Plc Amino-azabicycloalkyl derivatives as dopamine antagonists
GB2295387A (en) * 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
WO2003028641A2 (en) * 2001-10-01 2003-04-10 Taisho Pharmaceutical Co., Ltd. Mch receptor antagonists
CA2488635C (en) * 2002-06-12 2012-10-23 Abbott Laboratories Antagonists of melanin concentrating hormone receptor
EP1572212A2 (en) * 2002-12-11 2005-09-14 7TM Pharma A/S Quinoline compounds for use in mch receptor related disorders
CL2004000409A1 (en) * 2003-03-03 2005-01-07 Vertex Pharma COMPOUNDS DERIVED FROM 2- (REPLACED CILO) -1- (AMINO OR REPLACED OXI) -CHINAZOLINE, INHIBITORS OF IONIC SODIUM AND CALCIUM VOLTAGE DEPENDENTS; PHARMACEUTICAL COMPOSITION; AND USE OF THE COMPOUND IN THE TREATMENT OF ACUTE PAIN, CHRONIC, NEU
EP1844023A1 (en) * 2004-12-31 2007-10-17 Sk Chemicals Co., Ltd. Quinazoline derivatives for the treatment and prevention of diabetes and obesity

Also Published As

Publication number Publication date
AR056688A1 (en) 2007-10-17
UY29857A1 (en) 2007-05-31
WO2007042669A2 (en) 2007-04-19
FR2891829A1 (en) 2007-04-13
WO2007042669A3 (en) 2007-05-31

Similar Documents

Publication Publication Date Title
TW200732308A (en) Substituted 4-aminoquinazoline derivatives, preparation thereof and therapeutic application thereof
TW200716654A (en) Sulfoximine-macrocycle compounds and salts thereof, pharmaceutical compositions comprising said compounds, methods of preparing same and uses of same
TW200722079A (en) Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
UA95976C2 (en) 2-ARYL-6-PHENYLIMIDAZO[1,2-b]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
TW200714589A (en) Phenylacetamides suitable as protein kinase inhibitors
TW200621721A (en) Methods of preparing indazole compounds
TW200833690A (en) 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
NO20071197L (en) Sulfonamide derivatives, their preparation and their therapeutic use
MY139941A (en) Indole derivatives
MX2010003495A (en) Quinazolinedione derivatives, preparation thereof and therapeutic uses thereof.
TW200612948A (en) 2-substituted heteroaryl compounds
UA101819C2 (en) Herbicidal 1h-2-thia-1,5,8-triazanaphthalene-2,2-dioxides
CY1113676T1 (en) Substituted Beta-Finyl-Alpha-Hydroxy Propionic Acid, Method of Composition and Its Use
EA200700901A1 (en) DERIVATIVES 2-AMIDO-4-PHENYL THIAZOLE, THEIR OBTAINING AND USE IN THERAPY
UY29036A1 (en) DERIVATIVES OF OXOPIPERIDINE, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS
MX2007007027A (en) Piperazinyl pyridine derivatives as anti-obesity agents.
JO2682B1 (en) 7-ALkynyl-1,8-Naphthyridone Derivatives, Preparation Thereof And Therapeutic Use Thereof
TW200637817A (en) 5-aminoindole derivatives
DE602007001463D1 (en) PYRIMIDINE, CHINAZOLIN, PTERIDINE AND TRIAZINE DERIVATIVES
UY29859A1 (en) DERIVATIVES OF 1-AMINO-ISIQUINOLINE, ITS PREPARATION AND THERAPEUTIC APPLICATION
EA201070281A1 (en) INDOL-2-ONE DERIVATIVES, DOUBLE SUBSTITUTES IN POSITION 3, THEIR RECEIVING AND THEIR USE IN THERAPY
DE602005016282D1 (en) PROCESS FOR THE PREPARATION OF CAMPTOTHECIN DERIVATIVES
EA201100696A1 (en) 1- (ARILSULPHONIL) -4- (PIPERAZIN-1-IL) -1H-BENZIMIDAZOLES AS 5-HYDROXITRIPTAMINE-6 LIGANDS
MX2009000768A (en) Macrocyclic lactams.
TW200637829A (en) Sulfonamido-macrocycles as tie2 inhibitors and the salts thereof, a pharmaceutical composition comprising these compounds, the method of preparing and the use thereof